Scientific Research Services
ANZSIC group 691 · 27 mergers
Since January 2026, the ACCC has reviewed 27 acquisitions in the Scientific Research Services industry (ANZSIC group 691): 16 notified mergers and 11 waiver applications. Outcomes so far: 24 approved, 1 not approved and 2 still under assessment. The most frequent acquirers are Eli Lilly (6), Blackbird Ventures (3) and Gilead (2). Completed Phase 1 reviews took a median of 16 business days, and waivers a median of 14 business days. The most recent, Blackbird Ventures – Baseten Labs, was lodged on 4 November 2026.
Total reviews
27
Phase 2 reviews
0
Waivers
11
Under assessment
2
Sub-industries
Mergers in this industry
- ACURIO - Nepean, Sydney Southwest, and Campbelltown Private HospitalsUnder assessment
- Sun Pharma - OrganonUnder assessment
- Pemba – AccelagenApproved
- Novotech - AgilexApproved
- PSP – interest in AMP Grapes Investments LimitedApproved
- Blackbird Ventures – Baseten LabsApproved
- Blackbird Ventures - Heidi HealthApproved
- Eli Lilly – Merida BiosciencesApproved
- Advent – NZCR Group HoldingsApproved
- Novonesis – MicrobiogenApproved
- Eli Lilly - AtaiBeckley Inc.Approved
- Movac – Advanced NavigationApproved
- AbbVie - ApogeeApproved
- Vertex – CrineticsApproved
- Blackbird Ventures – Baseten LabsApproved
- Hexagon - Waygate TechnologiesApproved
- Eli Lilly - Kelonia TherapeuticsApproved
- Novartis - ExcellergyApproved
- Gilead - OuroApproved
- Eli Lilly – acquisition of licence from CSL BehringApproved
- Danaher - MasimoApproved
- Eli Lilly - Orna TherapeuticsApproved
- Gilead - ArcellxApproved
- Blackbird Ventures – HalterApproved
- Eli Lilly – Orna TherapeuticsNot approved
- Thermo Fisher - Clario HoldingsApproved
- Blackbird Ventures – Baseten LabsApproved